MY LIFE HEALTH

Nelson A. Alawode, MD
Obstetrics & Gynecology

HEALTH EDUCATION SERIES

Why the Name Change? The Story Behind PCOS Becoming PMOS (Part 2)

A 14-year, 56-organization effort to get the name right

When a medical name has been used for nearly 90 years, changing it is not a small thing. So when polycystic ovary syndrome (PCOS) officially became polyendocrine metabolic ovarian syndrome (PMOS) in May 2026, a lot of people had the same question: why now, and why at all? Here is the honest answer, in plain language.

> *New here? **Part 1 of this series**, "PCOS Has a New Name," covers symptoms, diagnosis, and treatment if you want the fuller picture first.*

The Old Name Was Misleading From the Start

“Polycystic ovary syndrome” puts all the attention on one detail: cysts on the ovaries. But that detail does not actually tell the full story of what is going on in the body, for two big reasons.

First, many people diagnosed with this condition do not have ovarian cysts at all. The “follicles” involved are actually small, immature egg sacs, not the painful or harmful cysts the word usually brings to mind. Second, and more importantly, the cysts are not the main driver of the condition’s most serious effects. The real engine behind PMOS is a tangle of hormonal and metabolic shifts — especially insulin resistance and elevated androgens — that influence everything from your menstrual cycle to your heart health.

In other words, the old name described a symptom that is not even present in everyone who has the condition, while leaving out the metabolic risks that matter most for long-term health.

What the Old Name Cost Patients

This was not just a naming inconvenience. Researchers point to real, measurable harm that came from the cyst-centered framing:

- Delayed diagnoses, because patients without visible cysts on an ultrasound were sometimes told they could not have the condition
- Confusion and fear, with many patients searching for cysts that were never the real issue
- Fragmented care, where reproductive symptoms were treated by one specialist while metabolic risks like insulin resistance and cardiovascular disease went unaddressed
- Stigma, from a name that sounded purely gynecological and overlooked the condition’s impact on mental health, skin, and weight
- Underfunded research and policy attention, since a name centered on “ovary” narrowed how the condition was studied and funded

These were not minor side effects of a naming choice. For a condition affecting more than 170 million women and girls worldwide — roughly 1 in 8 — a misleading name had an outsized impact on care.

How the New Name Was Chosen

This is the part people are often surprised by: the new name was not handed down by a small panel of specialists behind closed doors. It came out of a 14-year global consensus process, led by Monash University and involving 56 academic, clinical, and patient organizations from around the world.

More than 14,300 people — patients and health professionals across every world region — weighed in through surveys and workshops. The team running the process used structured methods (iterative surveys and group discussions) specifically designed to reach genuine agreement rather than a name picked by a handful of experts.

Through that process, six guiding principles emerged for what the new name needed to do:

- Reflect patient benefit — actually improve understanding and care, not just sound different
- Be scientifically accurate — describe what is really happening in the body

- Be easy to communicate — understandable to patients, not just specialists
- Avoid stigma — move away from language that felt embarrassing or confusing to say out loud
- Be culturally appropriate — translate and make sense across different languages and regions
- Be realistic to implement — something health systems could actually adopt over time

"Polyendocrine metabolic ovarian syndrome" was the name that best satisfied all six. It signals that multiple hormone systems are involved ("polyendocrine"), that metabolism is central to the condition, and that the ovaries are part of the picture without being the whole story.

The Numbers Behind the Decision

When the final proposed name was put to a vote among the patients and clinicians involved in the process, the support was strong and clear: 86 percent of patients and 71 percent of clinicians backed the change. That is a rare level of agreement for a medical naming decision, and it is part of why the consensus was published as a landmark moment in *The Lancet* rather than treated as a routine update.

What Happens Now

Name changes in medicine roll out gradually, not overnight. Here is what to expect:

- Your diagnosis and treatment plan do not change because of this announcement
- You will likely hear both "PCOS" and "PMOS" used interchangeably for the next few years
- The next major international clinical guideline update, expected in 2028, will be the point where PMOS becomes the standard term in official medical practice
- Patient materials, lab forms, and provider training will update gradually as health systems catch up

If your chart, prescription, or insurance paperwork still says PCOS for a while, that is expected and not a mistake.

A Note for Our Community Across Africa

Name changes can be slower to reach clinics with fewer resources or less access to international medical journals. If your provider has not heard of PMOS yet, you can still describe your symptoms and concerns using the language in this series — irregular periods, excess hair growth, insulin resistance, family history of diabetes — and ask specifically about the condition formerly known as PCOS. The underlying science and treatment options are the same no matter which name your local provider currently uses.

Why This Matters Beyond Semantics

A name shapes how seriously a condition is taken, how it gets funded, and how clearly patients can advocate for themselves. By centering the metabolic and hormonal reality of this condition, PMOS gives patients better language to ask for the full picture of care — not just a fertility conversation, but blood sugar screening, cholesterol checks, and mental health support too.

Your health matters. You matter.

Know more. Live better.

Sources: *Teede HJ, et al. "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process." The Lancet, May 12, 2026. World Health Organization. "Polycystic Ovary Syndrome" fact sheet, who.int. U.S. CDC, Division of Diabetes Translation. "Diabetes and Polycystic Ovary Syndrome (PCOS)," cdc.gov. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). "Polycystic Ovary Syndrome (PCOS)," nichd.nih.gov. European Congress of Endocrinology, Prague, May 2026 — consensus announcement proceedings.*

MY MY LIFE HEALTH

Scan QR Code to Visit our Website & Donate